Whole Blood Transcriptomic Signal According to Coronary Atherosclerotic Plaque Burden Assessed by CT Angiography

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-19

Study Completion Date

2028-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present clinical study aims to identify transcriptomic patterns derived from whole blood samples related to coronary atherotic burden. Additionally, as a secondary analysis, the research team will explore the algorithm's ability to detect the presence of aortic disease and pro-inflammatory cardiometabolic alterations, such as hepatic steatosis and surrogate markers of coronary inflammation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inflammation and Clotting Abnormalities in Aneurysmal Coronary Artery Disease

NCT05183373

Coronary Artery Aneurysm Abdominal Aortic Aneurysm Coronary Disease

UNKNOWN

Stratification of Patient With Carotid Disease

NCT03495830

Carotid Artery Stenosis

COMPLETED

The Biomechanical Study of Diseased Human Carotid, Femoral and Abdominal Aortic Tissue

NCT05802706

Vascular Diseases

RECRUITING

3D Contrast Enhanced Microvascular Ultrasound of Carotid Atherosclerosis for the Detection of Carotid Plaque Neo-Revascularisation.

NCT07298655

Carotid Atherosclerosis Ultrasound Plaque Neovascularization

RECRUITING NA

EValuation of Systemic Atherothrombosis in Patients With ARTerial Disease of the Lower Limbs

NCT01224600

Peripheral Arterial Disease Carotid Stenosis Abdominal Aortic Aneurysm

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be a prospective observational study. A convenience sample will be carried out to include 200 patients who attend the ENERI Medical Institute, La Sagrada Familia Clinic and Sanatorio Mendez with a clinical indication to be evaluated by a CCTA due to suspected CAD or known CAD. The study will have a baseline stage in which a clinical evaluation will be performed, blood samples will be drawn for transcriptome analysis and laboratory analysis. Then, a DNA sample obtained by swabbing the buccal mucose will be taken. Subsequently, the images obtained from the clinically indicated CCTA will be assessed to explore the outcomes of interest. At the end of patient enrollment, biological samples will be sequenced for in silico evaluation of the results. Finally, a 5-year follow-up will be carried out via telephone or email contact to collect data on the incidence of fatal and non-fatal cardiovascular events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Calcific Coronary Arteriosclerosis Coronary Stenosis Coronary Plaque Aortic Calcification Atherosclerotic Plaque

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women between 18 and 75 years, with a clinical indication to be evaluated by a CCTA due to suspected or known CAD.
* Signature of informed consent.

Exclusion Criteria

* Previously known chronic renal or hepatic insufficiency.
* Active chronic lung disease, defined as: exacerbated asthma, exacerbated COPD, or pulmonary fibrosis.
* Myocardial infarction, unstable angina, cerebrovascular accident, or vascular interventions (any territory) in the past 6 months.
* Implantation of drug-eluting stents in the last 12 months.
* Revascularization surgery (By-pass)
* Indication of Angio-CT for congenital heart disease or Transcatheter Aortic Valve Replacement (TAVI)
* Presence/ diagnosis of heart failure symptoms or signs (ie. dyspnea, asthenia, edema) with objective evidence of pulmonary or systemic congestion at rest or with exercise in the last 6 months.
* Left ventricular ejection fraction \<50% confirmed by objective diagnostic methods (eg doppler echocardiogram).
* Severe valvulopathies, confirmed by objective diagnostic methods (eg doppler echocardiogram).
* Uncontrolled hyper or hypothyroidism.
* Suprarenal insufficiency.
* Previous surgeries in the last 3 months.
* Severe trauma in the last 6 months, defined as one that involved bone fractures and/or surgical interventions.
* Known active cancer disease or under treatment (acute or preventive), or history of cancer disease without criteria for cure.
* Diagnosis of active autoimmune disease or any pathology under immunosuppressive treatment.
* Ongoing pregnancy, postpartum period of less than 12 months or breastfeeding.
* Other serious diseases with an estimated life expectancy of less than 12 months (according to the investigator's opinion).
* Temperature greater than 37.5°C recorded by a thermometer or any acute infection caused by viruses or bacteria confirmed by a health professional in the previous 30 days.
* Pacemaker/Cardio-Defibrillator Implantation.
* Prior to the study: heart rate \> 70 l/m or atrial fibrillation or frequent extrasystoles that in the opinion of the specialist physician will affect the quality of the cardiovascular imaging.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No